|Bid||89.20 x 800|
|Ask||89.26 x 800|
|Day's Range||88.56 - 89.49|
|52 Week Range||61.13 - 93.04|
|Beta (5Y Monthly)||1.12|
|PE Ratio (TTM)||40.89|
|Earnings Date||Aug. 12, 2020 - Aug. 17, 2020|
|Forward Dividend & Yield||0.72 (0.82%)|
|Ex-Dividend Date||Jun. 29, 2020|
|1y Target Est||90.17|
Yahoo Finance’s Alexis Christoforous, Brian Sozzi, and Andy Serwer discuss the cost of developing a COVID-19 vaccine in such a short time, and why that money is worthwhile.
Zacks.com featured highlights include: Lowes Companies, Charles River Laboratories International, Agilent Technologies and East West
If you're looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy.
Agilent Technologies Inc. (NYSE: A) today announced two new mass spectrometry (MS) products: the Agilent 6470B Triple Quadrupole LC/MS (6470 LC/TQ) system, and the Agilent RapidFire 400 system. Both deliver even faster detection of target compounds providing customers increased sample throughput and reduced time to generate results. The instruments are being introduced at ASMS 2020 Reboot, the interactive, online version of the annual conference of the American Society for Mass Spectrometry, being held June 1-12, 2020.
Agilent's (A) second-quarter fiscal 2020 results reflect negative impact of coronavirus outbreak despite robust performance of the Diagnostics and Genomics Group.
Thank you, Jodi, and welcome everyone to Agilent's conference call for the second quarter of fiscal year 2020. On the webcast today are Mike McMullen, Agilent's President and CEO; and Bob McMahon, Agilent's Senior Vice President and CFO. Joining for the Q&A after prepared remarks will be Jacob Thaysen, President of Agilent's Life Science and Applied Markets Group; and Sam Raha, President of Agilent's Diagnostics and Genomics Group, along with Padraig McDonnell, President of the Agilent CrossLab Group.
Agilent (A) delivered earnings and revenue surprises of 22.41% and 5.23%, respectively, for the quarter ended April 2020. Do the numbers hold clues to what lies ahead for the stock?
Agilent (A) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Agilent Technologies Inc. (NYSE: A) announces that biotech startup Trilogy Sciences has been awarded an Agilent Golden Ticket at LabCentral, a leading biotech innovation hub based in Cambridge, Massachusetts. LabCentral is a shared laboratory space designed as a launchpad for high-potential life sciences and biotech startups. The Golden Ticket provides funding of one lab bench space for a year.
When we invest, we're generally looking for stocks that outperform the market average. And the truth is, you can make...
Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration has approved the company’s PD-L1 IHC 22C3 pharmDx as a companion diagnostic (CDx) to identify patients with non-small cell lung cancer who are appropriate for first-line monotherapy with KEYTRUDA (pembrolizumab) on the Dako Omnis platform.
Agilent Technologies Inc. (NYSE: A) announced today that it has become a top-level sponsor of My Green Lab, a nonprofit organization dedicated to improving the sustainability of scientific research.
Agilent provides update on COVID-19 impact and sets second-quarter earnings call for May 21.